Zydus Lifesciences Limited will participate in the Motilal Oswal 22nd Annual Global Investor Conference on August 18, 2026. The company disclosed this engagement to provide investors with an opportunity to interact with management regarding its strategic direction and business updates. This appearance serves as a key communication channel for stakeholders seeking direct insights from the pharmaceutical firm’s leadership team.

The disclosure was filed with both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 10, 2026. The filing ensures that all exchange members and investors at large are aware of the upcoming investor interaction event.

Event Details

The conference is organized by Motilal Oswal Financial Services. Zydus Lifesciences is scheduled to take part in the proceedings on August 18, 2026. The company did not specify a particular time slot or session format in the initial disclosure.

Regulatory Compliance

The announcement was authorized by Dhal Narenda Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited. The filing carries membership number FCS7063 and was digitally signed on August 10, 2026, at 09:37:40 +05'30'.

Zydus Lifesciences Limited maintains its registered office at 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. The company’s Corporate Identification Number (CIN) is L24230GJ1995PLC025878.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Indocyanine Green for Injection, USP, 25 mg/vial. The regulator has designated the application as a Competitive Generic Therapy (CGT), granting the company eligibility for 180 days of market exclusivity upon first commercial marketing. This approval strengthens Zydus' position in the US generics market, particularly in the complex imaging agent segment.

The approved product is a sterile lyophilised powder for reconstitution, supplied as a kit with single-patient-use vials of Indocyanine Green and Sterile Water for Injection. It serves as a generic equivalent to Diagnostic Green LLC’s reference listed drug, IC-Green®. Indocyanine Green is an optical imaging agent used for fluorescence imaging of vessels, blood flow, and tissue perfusion during vascular, gastrointestinal, organ transplant, and reconstructive surgeries. It is also indicated for imaging extrahepatic biliary ducts, lymphatic mapping in cervical and uterine cancer patients, and ophthalmic angiography in adults and paediatric patients aged one month and older.

Key Approval Details

The following table outlines the specifics of the regulatory milestone:

Market Potential and Portfolio Growth

The brand product, IC-Green®, reported annual sales of approximately USD 125.8 mn in the United States, representing a 61.0% growth, with volumes rising 27.1% to 0.64 mn units, according to IQVIA MAT June-2026 data. Zydus plans to launch the product shortly to trigger the 180-day exclusivity period. The product will be manufactured at the group’s USFDA-approved injectable plant in Jarod and marketed in the US by Zydus Pharmaceuticals (USA) Inc.

This approval adds to Zydus’ growing portfolio of complex injectables and imaging products. As of June 30, 2026, the group holds 445 USFDA approvals and has filed 513 ANDAs. Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, noted that securing approval for such a complex product reflects the company’s capabilities in chromophore purity and lyophilisation control. He emphasized that this development advances their goal of making essential diagnostics more accessible while strengthening their presence in the functional dye segment.

What the Numbers Show

The significant growth in the brand product’s sales volume (27.1%) and value (61.0%) indicates a robust and expanding addressable market for indocyanine green in the US. By entering with CGT exclusivity, Zydus positions itself to capture a substantial share of this growing niche before other generic competitors can enter. This move aligns with the company’s broader strategy of leveraging internal formulation expertise combined with external partnerships to develop complex generics, thereby diversifying revenue streams beyond standard therapeutic categories.